Avoro Capital Advisors LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001633313

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 29 positions · Total reported value $9.67B · Top-10 concentration 83.5% · Updated 2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

Turnover: 62.1% · 3 new · 15 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -15.9% · vs SPY -18.0% · Prev Value $11.14B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -0.4% · vs SPY -2.6% · Latest Value $9.67B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Avoro Capital Advisors LLC disclosed 29 equity positions with a combined reported value of $9.67B. The filing implies a focused portfolio: its ten largest positions account for 83.5% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were UTHR ($1.49B), ASND ($1.15B), KRYS ($960.73M). By sector, the heaviest allocations are Health Care 99.6%, Other 0.4%.

Versus the prior quarter, Avoro Capital Advisors LLC opened 3 new positions, trimmed 15 and fully exited 0, a turnover rate of 62.1% of positions. The portfolio's overlap with the prior quarter was 90% of names.

The largest new positions opened in Q3 2026 were ABVX ($48.32M), SYRE ($47.83M), BHVN ($36.71M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • ABVX ABIVAX SA · $48.32M
  • SYRE SPYRE THERAPEUTICS INC · $47.83M
  • BHVN BIOHAVEN LTD · $36.71M

Fully Exited (vs previous quarter)

No tracked position was fully exited this quarter.

Insider Transactions (Form 4)

Latest Avoro Capital Advisors LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-07-28 Buy Scribe Therapeutics, Inc. 7,905 $18.25 SEC filing
2026-07-24 Buy Scribe Therapeutics, Inc. 50,000 $22.31 SEC filing
2026-07-24 Buy Scribe Therapeutics, Inc. 2,333,333 $15.00 SEC filing

All insider transactions →

Fund Profile

Avoro Capital Advisors LLC is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 26 US equity positions with a combined value of $11.14B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-74391 (status: Approved), registered 2012-03-30
  • Regulatory AUM (Form ADV): $13.55B as of 2026-03-05
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 2 private funds, of which 1 hedge funds
  • Website: avorocapital.com

Portfolio Structure

  • 26 positions · $11.14B reported value (Q2 2026)
  • Top 10 holdings = 79.5% of reported value
  • Largest position: UTHR (UNITED THERAPEUTICS CORP DEL) at 13.5%
  • Average position size: $428.32M

Sector Tilt

  • Health Care 99.7%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 2 new, 12 added, 3 reduced, 6 exited
  • 9 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund reduced exposure to multiple biotech/healthcare names (6 of top 10), suggesting cautiousness or profit-taking in a volatile sector, while maintaining core holdings. 2. Key moves: - Reduced: UTHR (-0.8% shares), ASND (-1.2%), ARWR (-3.1%), RVMD (-6.6%), CYTK (-2.0%), DFTX (-1.9%). - Held: KRYS, ARGX, MDGL, KYMR (no share changes). - Added: No top-10 additions (3 new positions not listed). 3. Portfolio structure: Active, concentrated (29 positions), heavily biased toward Health Care (100% of top 10), with high risk (small/mid-cap biotech focus). 4. Per-holding one-liner: - UTHR: Pulmonary hypertension drugs (United Therapeutics). - ASND: Growth disorders therapy (Ascendis Pharma). - KRYS: Gene therapy for rare diseases (Krystal Biotech). - ARGX: Autoimmune/immunology drugs (Argenx). - MDGL: NASH/fatty liver drugs (Madrigal Pharmaceuticals). - KYMR: Dermatology/innate immunity drugs (Kymera Therapeutics). - ARWR: RNA therapeutics (Arrowhead Pharmaceuticals). - RVMD: Cancer/RAS pathway drugs (Revolution Medicines). - CYTK: Cardiomyopathy drugs (Cytokinetics). - DFTX: Gene therapy platform (Definium Therapeutics). 5. Style summary: Biotech-focused active manager trimming speculative positions while retaining core clinical-stage drug developers.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 03:55

Sector Allocation

Health Care 99.6%
Other 0.4%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 2.76M $1.49B 15.45%
15.45%
Reduce
2 5.05M $1.15B 11.90%
11.90%
Reduce
3 2.89M $960.73M 9.94%
9.94%
Hold
4 1.00M $958.91M 9.92%
9.92%
Hold
5 1.83M $923.93M 9.56%
9.56%
Hold
6 7.47M $835.60M 8.64%
8.64%
Hold
7 11.00M $719.95M 7.45%
7.45%
Reduce
8 2.15M $440.28M 4.55%
4.55%
Reduce
9 4.90M $322.96M 3.34%
3.34%
Reduce
10 7.05M $268.32M 2.78%
2.78%
Reduce
11 6.56M $204.99M 2.12%
2.12%
Hold
12 5.50M $204.54M 2.12%
2.12%
Reduce
13 5.63M $181.95M 1.88%
1.88%
Reduce
14 6.73M $162.54M 1.68%
1.68%
Hold
15 1.50M $119.28M 1.23%
1.23%
Reduce
16 23.89M $116.34M 1.20%
1.20%
Hold
17 12.38M $94.96M 0.98%
0.98%
Reduce
18 3.78M $80.50M 0.83%
0.83%
Hold
19 1.89M $58.36M 0.60%
0.60%
Reduce
20 2.50M $51.48M 0.53%
0.53%
Hold
21 1.30M $50.87M 0.53%
0.53%
Reduce
22 488.00K $48.32M 0.50%
0.50%
New
23 2.60M $47.83M 0.49%
0.49%
New
24 1.41M $41.93M 0.43%
0.43%
Reduce
25 1.77M $41.56M 0.43%
0.43%
Reduce
26 2.75M $36.71M 0.38%
0.38%
New
27 2.38M $36.45M 0.38%
0.38%
Add
28 2.85M $10.71M 0.11%
0.11%
Hold
29 525.00K $1.77M 0.02%
0.02%
Reduce

FAQ

What did Avoro Capital Advisors LLC buy in 2026-Q3?

In its 2026-Q3 13F filing, Avoro Capital Advisors LLC reported 29 equity positions worth $9.67B in aggregate; its largest disclosed positions were UTHR ($1.49B), ASND ($1.15B), KRYS ($960.73M).

How large is Avoro Capital Advisors LLC's portfolio?

Avoro Capital Advisors LLC reported $9.67B of long equity holdings across 29 positions as of 2026-Q3. Top-10 holdings account for 83.5% of reported value.

What is Avoro Capital Advisors LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/avoro-capital-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →